Trial Profile
A randomized, double-blind, vehicle-controlled, multicenter trial of topically administered LDE225 cream [0.75% bid] to evaluate clearance of Basal Cell Carcinoma in adult patients with Nevoid Basal Cell Carcinoma Syndrome
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 08 May 2017
Price :
$35
*
At a glance
- Drugs Sonidegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 11 Apr 2014 New trial record